Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.

Article  CAS  PubMed  Google Scholar 

Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134:783–91. https://doi.org/10.1097/CM9.0000000000001474.

Article  PubMed  Google Scholar 

Coleridge SL, Bryant A, Lyons TJ, Goodall RJ, Kehoe S, Morrison J. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2019. https://doi.org/10.1002/14651858.CD005343.pub4.

Article  PubMed  PubMed Central  Google Scholar 

Coosemans A, Vankerckhoven A, Baert T, Boon L, Ruts H, Riva M, Blagden S, Delforge M, Concin N, Mirza MR, Ledermann JA, du Bois A, Vergote I. Combining conventional therapy with immunotherapy: a risky business? Eur J Cancer. 2019;113:41–4. https://doi.org/10.1016/j.ejca.2019.02.014.

Article  CAS  PubMed  Google Scholar 

Penson RT. Platinum-sensitive ovarian cancer: liminal advances. Lancet Oncol. 2020;21:614–5. https://doi.org/10.1016/S1470-2045(20)30178-9.

Article  PubMed  Google Scholar 

Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, Bamias A, Salutari V, Selle F, Frezzini S, De Giorgi U, Pautier P, Bologna A, Orditura M, Dubot C, Gadducci A, Mammoliti S, Ray-Coquard I, Zafarana E, Breda E, Favier L, Ardizzoia A, Cinieri S, Largillier R, Sambataro D, Guardiola E, Lauria R, Pisano C, Raspagliesi F, Scambia G, Daniele G, Perrone F, Investigators MIbM-OE-o. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol. 2021;22:267–76. https://doi.org/10.1016/S1470-2045(20)30637-9.

Article  CAS  PubMed  Google Scholar 

Ngoi NYL, Tay D, Heong V, Thian YL, Ong PY, Ow SGW, Jeyasekharan AD, Lim YW, Lim SE, Lee SC, Ng J, Low JJH, Ilancheran A, Koh SZL, Tan DSP. Reversal of bowel obstruction with platinum-based chemotherapy and olaparib in recurrent, short platinum-free interval, RAD51C germline mutation-associated ovarian cancer. JCO Precis Oncol. 2018;2:1–8. https://doi.org/10.1200/PO.18.00008.

Article  PubMed  Google Scholar 

Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou J, Lu Y, Shi Y, Wang Z, Jiang L, Luo Y, Zhang Y, Huang C, Li Q, Wu G. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018;118:654–61. https://doi.org/10.1038/bjc.2017.478.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, Yu H, Zhao Y, Chen W, Luo Y, Wu L, Wang X, Pirker R, Nan K, Jin F, Dong J, Li B, Sun Y. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018;4:1569–75. https://doi.org/10.1001/jamaoncol.2018.3039.

Article  PubMed  PubMed Central  Google Scholar 

Chen S, Gao Y, Zhu P, Wang X, Zeng L, Jin Y, Zhi X, Yang H, Zhou P. Anti-cancer drug anlotinib promotes autophagy and apoptosis in breast cancer. Front Biosci (Landmark Ed). 2022;27:125. https://doi.org/10.31083/j.fbl2704125.

Article  CAS  PubMed  Google Scholar 

Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69:280–304. https://doi.org/10.3322/caac.21559.

Article  PubMed  Google Scholar 

Pujade-Lauraine E, Combe P. Recurrent ovarian cancer. Ann Oncol. 2016;27(Suppl 1):i63–5. https://doi.org/10.1093/annonc/mdw079.

Article  PubMed  Google Scholar 

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. https://doi.org/10.1016/j.cell.2011.02.013.

Article  CAS  PubMed  Google Scholar 

Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol. 2013;25:50–1. https://doi.org/10.1097/CCO.0b013e32835b651e.

Article  PubMed  Google Scholar 

Syed YY. Anlotinib: first global approval. Drugs. 2018;78:1057–62. https://doi.org/10.1007/s40265-018-0939-x.

Article  CAS  PubMed  Google Scholar 

Zhu Y, Wang X, Chen Z, Zhou L, Di X, Fan P, He Z. Anlotinib suppressed ovarian cancer progression via inducing G2/M phase arrest and apoptosis. J Clin Med. 2022. https://doi.org/10.3390/jcm12010162.

Article  PubMed  PubMed Central  Google Scholar 

Lopes-Coelho F, Martins F, Pereira SA, Serpa J. Anti-angiogenic therapy: current challenges and future perspectives. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22073765.

Article  PubMed  PubMed Central  Google Scholar 

Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039–45. https://doi.org/10.1200/JCO.2012.42.0505.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bamias A, Gibbs E, Khoon Lee C, Davies L, Dimopoulos M, Zagouri F, Veillard AS, Kosse J, Santaballa A, Mirza MR, Tabaro G, Vergote I, Bloemendal H, Lykka M, Floquet A, Gebski V, Pujade-Lauraine E. Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. Ann Oncol. 2017;28:1842–8. https://doi.org/10.1093/annonc/mdx228.

Article  CAS  PubMed  Google Scholar 

Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O’Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:779–91. https://doi.org/10.1016/S1470-2045(17)30279-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang G, Sun M, Jiang Y, Zhang T, Sun W, Wang H, Yin F, Wang Z, Sang W, Xu J, Mao M, Zuo D, Zhou Z, Wang C, Fu Z, Wang Z, Duan Z, Hua Y, Cai Z. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. Int J Cancer. 2019;145:979–93. https://doi.org/10.1002/ijc.32180.

Article  CAS  PubMed  Google Scholar 

Rossi L, Verrico M, Zaccarelli E, Papa A, Colonna M, Strudel M, Vici P, Bianco V, Tomao F. Bevacizumab in ovarian cancer: a critical review of phase III studies. Oncotarget. 2017;8:12389–405. https://doi.org/10.18632/oncotarget.13310.

Article  PubMed  Google Scholar 

Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16:928–36. https://doi.org/10.1016/S1470-2045(15)00086-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu JF, Matulonis UA. Bevacizumab in newly diagnosed ovarian cancer. Lancet Oncol. 2015;16:876–8. https://doi.org/10.1016/S1470-2045(15)00064-9.

Article  CAS  PubMed  Google Scholar